Close

CPIC® guideline for statins and SLCO1B1, ABCG2, and CYP2C9

Most recent guideline publication:

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022)

Updates since publication:

none

Tables provided in the main manuscript of the guideline:

Table 1. Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype
Table 2. Dosing recommendations for statins based on SLCO1B1 phenotype in adults
Table 3. Dosing recommendations for rosuvastatin based on ABCG2 phenotype in Adults
Table 4. Dosing recommendations for fluvastatin based on CYP2C9 phenotype in Adults
Table 5. Combined recommendation for rosuvastatin based on SLCO1B1 and ABCG2 phenotype In Adults
Table 6. Combined recommendation for fluvastatin based on SLCO1B1 and CYP2C9 phenotype in Adults
Figure 1. SLCO1B1 recommendations with intensity and statin dose stratified by SLCO1B1 phenotype; all doses assume adult dosing.

Supplement to:

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022)

Tables and figures included in the supplementa or referenced in the guideline:

Supplemental Figure S1. Pharmacokinetic impact of rs4149056 genotype for several statins
Table S1. Evidence linking SLCO1B1 genotype with Statin phenotype
Table S2. Evidence linking ABCG2 genotype with Statin phenotype
Table S3. Evidence linking CYP2C9 genotype with Statin phenotype
Table S4. Evidence linking HMGCR genotype with Statin phenotype
Table S5. Evidence linking CYP3A4/5 genotype with Statin phenotype
SLCO1B1 allele definition table
SLCO1B1 allele functionality table
SLCO1B1 frequency table
SLCO1B1 diplotype-phenotype table
ABCG2 allele definition table
ABCG2 allele functionality table
ABCG2 frequency table
ABCG2 diplotype-phenotype table
CYP2C9 allele definition table
CYP2C9 allele functionality table
CYP2C9 frequency table
CYP2C9 diplotype-phenotype table
Gene resource mapping:

SLCO1B1 gene resource mappings

ABCG2 gene resource mappings

CYP2C9 gene resource mappings

Drug resource mapping:

Atorvastatin

Fluvastatin

Lovastatin

Rosuvastatin

Pitavastatin

Pravastatin

Simvastatin

Clinical decision support:b

SLCO1B1 consult and implementation workflow

ABCG2 consult and implementation workflow

CYP2C9 consult and implementation workflow

Atorvastatin pre- and post-test alerts and flow chart

Fluvastatin pre- and post-test alerts and flow chart

Lovastatin pre- and post-test alerts and flow chart

Pitavastatin pre- and post-test alerts and flow chart

Pravastatin pre- and post-test alerts and flow chart

Rosuvastatin pre- and post-test alerts and flow chart

Simvastatin pre- and post-test alerts and flow chart

aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.

bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.

2014 guideline:

Original publication (July 2012)

This guideline has been endorsed by the American Society of Health-System Pharmacists (ASHP).